Frontage Laboratories announced the completion of the acquisition of Teddy Clinical Research Laboratory, a clinical research laboratory service provider in China. The acquisition aims to enhance Frontage's global laboratory service capabilities and further strengthen its presence in China and the Asia-Pacific region.
Teddy Lab is a recognized clinical research laboratory with extensive experience supporting more than 1,500 clinical trials across multiple therapeutic areas. The company is known for its GCP-compliant operations and internationally accredited laboratory services. Teddy Lab operates under CAP-accredited and NGSP Level 1 certified quality systems, as well as qualification as a Class II Unsealed Radioactive Material Workplace, providing pharmaceutical and biotechnology partners with reliable, audit-ready laboratory services that meet global regulatory standards. Its strong track record includes supporting regulatory inspections and contributing to the successful marketing approval of 50 new drugs.
As a result of the transaction, Frontage has expanded its central laboratory footprint in China, which it expects to leverage in supporting the increasing demand for both domestic China and multi-regional clinical trials (MRCT). By integrating Teddy Lab's central laboratory expertise with Frontage's comprehensive service platform – including bioanalytical, DMPK, safety and toxicology, CMC, and clinical trial support – Frontage hopes to further solidify its position as a trusted partner in the clinical research industry.